A measure supported prostate cancer

Treatment of prostate cancer is more tailored, say experts on the seventh day of the prostate of the French Association of Urology (AFU), held today. Fits "tumor characteristics (size, aggressiveness), the life expectancy of the patient and her choice of life (sexuality)," says Professor Pascal Rischmann (CHU de Toulouse). This is the most common male cancer (71,500 new cases per year). It is the second leading cause of death in men for cancer, after lung, but the first years after age 50, according to the AFU. It affects one in every six men between 60 and 79. This day is an opportunity for the EBA (www.urofrance.org) to inform about the different ways of treating this disease that is causing about 9,000 deaths a year. Council EBA: check 55 years to 69 years from 45 years in cases such as family history of cancer.
"A mosaic of cancer"


Today, many tumors are detected at an early stage when the disease is still localized, while there are a couple of decades, often being diagnosed at an advanced stage. In France, the mortality rate every year decrease of approximately 7% per year since late 1990, according to Professor Rischmann. Exchanges within the team (urologists, oncologists, radiotherapists, nurses ...) are designed to tailor treatment to each patient, avoiding over-treatment or therapy. "There is a cancer of the prostate, but a mosaic of cancers," says Professor Thierry Lebret. "So there's a lot of support and the first time that the administration is thinking," said the urologist.

In most cases, prostate cancer grows slowly from 10 to 15 years. Therefore, do not treat all patients, but the forecast could be initiated.